Help transform cancer care – Survey for patients & caregivers
Your Voice Matters!
Share your experience with subcutaneous (SQ) administration. Even if you have not received SQ we urge you to fill out this survey.
Many anticancer treatments are administered intravenously (IV). Some current IV cancer drugs, including one for kidney cancer, will soon be available for subcutaneous (SQ) administration (injection between the skin and muscle).
Kidney Cancer Canada is working with other patient groups to gather insights on patient experiences, preferences, and expectations regarding SQ administration. This feedback will help shape the recommendations submitted to health authorities like the Canadian Drug Agency (CDA) and pan-Canadian Oncology Drug Review (pCODR).
Even if you haven’t received subcutaneous (SQ) treatment for your condition, your perspective is crucial! We welcome patients and caregivers to participate in a survey so we can:
- Learn about your experience with your current treatment
- Learn about your awareness/opinion of subcutaneous drug administration.
Please watch the informational video below to learn more about SQ administration, its benefits, and how it might improve cancer treatment experiences.
